Antineoplastics

Antineoplastics Reactions 1704, p38 - 2 Jun 2018 Various toxicities and drug resistance leading to treatment failure: case report A 32-year-old woman developed hair loss, vomiting and neutropenia following treatment with etoposide, methotrexate, dactinomycin [Act-D], cyclophosphamide and vincristine for gestational trophoblastic neoplasia. Additionally, she developed resistance to methotrexate leading to treatment failure for gestational trophoblastic neoplasia [routes, durations of treatments to reactions onsets and outcomes not stated]. The woman (Gravida 2 para 0), who had metastatic gestational trophoblastic neoplasia, received single-agent chemotherapy with methotrexate. However, she developed resistance to methotrexate, leading to treatment failure. Hence multi-agent treatment (EMA-CO regimen) with etoposide, methotrexate, dactinomycin, cyclophosphamide and vincristine was started. Subsequently, she developed hair loss, vomiting and neutropenia. She received the EMA-CO regimen for a total duration of 5 months. Author comment: "[T]reatment with EMA-CO was generally well tolerated and toxicity was mild. In our case, there was no life-threatening toxicity, but hair loss, vomiting and neutropenia occurred. After suction evacuation, initially single agent chemotherapy using Methotrexate was done. However, this treatment failed. The patient with metastatic low risk GTN that developed resistance to single-agent chemotherapy achieved remission with combination chemotherapy." Han JS, et al. Coexisting complete hydatidiform mole and live foetus: A case report. Australasian Medical Journal 11: 227-230, No. 4, Jan 2018. Available from: URL: https://doi.org/10.21767/AMJ.2018.3379 - South Korea 803323079 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Antineoplastics

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/antineoplastics-MiaQCt8se2
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46681-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p38 - 2 Jun 2018 Various toxicities and drug resistance leading to treatment failure: case report A 32-year-old woman developed hair loss, vomiting and neutropenia following treatment with etoposide, methotrexate, dactinomycin [Act-D], cyclophosphamide and vincristine for gestational trophoblastic neoplasia. Additionally, she developed resistance to methotrexate leading to treatment failure for gestational trophoblastic neoplasia [routes, durations of treatments to reactions onsets and outcomes not stated]. The woman (Gravida 2 para 0), who had metastatic gestational trophoblastic neoplasia, received single-agent chemotherapy with methotrexate. However, she developed resistance to methotrexate, leading to treatment failure. Hence multi-agent treatment (EMA-CO regimen) with etoposide, methotrexate, dactinomycin, cyclophosphamide and vincristine was started. Subsequently, she developed hair loss, vomiting and neutropenia. She received the EMA-CO regimen for a total duration of 5 months. Author comment: "[T]reatment with EMA-CO was generally well tolerated and toxicity was mild. In our case, there was no life-threatening toxicity, but hair loss, vomiting and neutropenia occurred. After suction evacuation, initially single agent chemotherapy using Methotrexate was done. However, this treatment failed. The patient with metastatic low risk GTN that developed resistance to single-agent chemotherapy achieved remission with combination chemotherapy." Han JS, et al. Coexisting complete hydatidiform mole and live foetus: A case report. Australasian Medical Journal 11: 227-230, No. 4, Jan 2018. Available from: URL: https://doi.org/10.21767/AMJ.2018.3379 - South Korea 803323079 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off